104 related articles for article (PubMed ID: 26995061)
1. Bevacizumab and cetuximab with conventional chemotherapy reduced pancreatic tumor weight in mouse pancreatic cancer xenografts.
Tai CJ; Wang H; Wang CK; Tai CJ; Huang MT; Wu CH; Chen RJ; Kuo LJ; Wei PL; Chang YJ; Chang CC; Chiou HY; Wu CJ
Clin Exp Med; 2017 May; 17(2):141-150. PubMed ID: 26995061
[TBL] [Abstract][Full Text] [Related]
2. An Intergroup Randomized Phase II Study of Bevacizumab or Cetuximab in Combination with Gemcitabine and in Combination with Chemoradiation in Patients with Resected Pancreatic Carcinoma: A Trial of the ECOG-ACRIN Cancer Research Group (E2204).
Berlin JD; Feng Y; Catalano P; Abbruzzese JL; Philip PA; McWilliams RR; Lowy AM; Benson AB; Blackstock AW
Oncology; 2018; 94(1):39-46. PubMed ID: 29040974
[TBL] [Abstract][Full Text] [Related]
3. Combination of Two Targeted Medications (Bevacizumab Plus Cetuximab) Improve the Therapeutic Response of Pancreatic Carcinoma.
Tai CJ; Huang MT; Wu CH; Wang CK; Tai CJ; Chang CC; Hsieh CI; Chang YJ; Wu CJ; Kuo LJ; Wei PL; Chen RJ; Chiou HY
Medicine (Baltimore); 2016 Apr; 95(15):e3259. PubMed ID: 27082562
[TBL] [Abstract][Full Text] [Related]
4. Cetuximab reduces the accumulation of radiolabeled bevacizumab in cancer xenografts without decreasing VEGF expression.
Heskamp S; Boerman OC; Molkenboer-Kuenen JD; Sweep FC; Geurts-Moespot A; Engelhardt MS; van der Graaf WT; Oyen WJ; van Laarhoven HW
Mol Pharm; 2014 Nov; 11(11):4249-57. PubMed ID: 25294389
[TBL] [Abstract][Full Text] [Related]
5. Efficacy of combination chemotherapy using a novel oral chemotherapeutic agent, TAS-102, together with bevacizumab, cetuximab, or panitumumab on human colorectal cancer xenografts.
Tsukihara H; Nakagawa F; Sakamoto K; Ishida K; Tanaka N; Okabe H; Uchida J; Matsuo K; Takechi T
Oncol Rep; 2015 May; 33(5):2135-42. PubMed ID: 25812794
[TBL] [Abstract][Full Text] [Related]
6. Integration of novel agents in the treatment of colorectal cancer.
Iqbal S; Lenz HJ
Cancer Chemother Pharmacol; 2004 Sep; 54 Suppl 1():S32-9. PubMed ID: 15309512
[TBL] [Abstract][Full Text] [Related]
7. Antitumor activity of cetuximab associated with the taxotere-cisplatin-fluorouracil (TPF) combination on an orthotopic head and neck cancer model.
Bozec A; Sudaka A; Etienne-Grimaldi MC; Brunstein MC; Fischel JL; Milano G
Oral Oncol; 2011 Oct; 47(10):940-5. PubMed ID: 21862388
[TBL] [Abstract][Full Text] [Related]
8.
Yoshii Y; Matsumoto H; Yoshimoto M; Oe Y; Zhang MR; Nagatsu K; Sugyo A; Tsuji AB; Higashi T
J Nucl Med; 2019 Oct; 60(10):1437-1443. PubMed ID: 30850497
[TBL] [Abstract][Full Text] [Related]
9. Bevacizumab reduces tumor targeting of antiepidermal growth factor and anti-insulin-like growth factor 1 receptor antibodies.
Heskamp S; Boerman OC; Molkenboer-Kuenen JD; Oyen WJ; van der Graaf WT; van Laarhoven HW
Int J Cancer; 2013 Jul; 133(2):307-14. PubMed ID: 23335047
[TBL] [Abstract][Full Text] [Related]
10. Impact of BRAF and RAS mutations on first-line efficacy of FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab: analysis of the FIRE-3 (AIO KRK-0306) study.
Stintzing S; Miller-Phillips L; Modest DP; Fischer von Weikersthal L; Decker T; Kiani A; Vehling-Kaiser U; Al-Batran SE; Heintges T; Kahl C; Seipelt G; Kullmann F; Stauch M; Scheithauer W; Held S; Moehler M; Jagenburg A; Kirchner T; Jung A; Heinemann V;
Eur J Cancer; 2017 Jul; 79():50-60. PubMed ID: 28463756
[TBL] [Abstract][Full Text] [Related]
11. Time-dependent pretreatment with bevacuzimab increases tumor specific uptake of cetuximab in preclinical oral cavity cancer studies.
Chung TK; Warram J; Day KE; Hartman Y; Rosenthal EL
Cancer Biol Ther; 2015; 16(5):790-8. PubMed ID: 25719497
[TBL] [Abstract][Full Text] [Related]
12. [Screening for predictive biomarkers of bevacizumab treatment in gastric cancer subcutaneous xenografts].
Zhang Q; Xu J; Ye J; Yuan Y; Chen J; Peng J; He Y
Zhonghua Wei Chang Wai Ke Za Zhi; 2015 Feb; 18(2):177-80. PubMed ID: 25656129
[TBL] [Abstract][Full Text] [Related]
13. Effect of bevacizumab combined with chemotherapy at different sequences in the gastric-cancer-bearing nude mice.
Lv Y; Song L; Chang L; Zhang X; Liu Y; Liu W
J Cancer Res Ther; 2018; 14(Supplement):S190-S196. PubMed ID: 29578172
[TBL] [Abstract][Full Text] [Related]
14. Pharmacodynamics of DT-IgG, a dual-targeting antibody against VEGF-EGFR, in tumor xenografted mice.
Hurwitz SJ; Zhang H; Yun S; Batuwangala TD; Steward M; Holmes SD; Rycroft D; Pan L; Tighiouart M; Shin HJ; Koenig L; Wang Y; Chen ZG; Shin DM
Cancer Chemother Pharmacol; 2012 Mar; 69(3):577-90. PubMed ID: 21913035
[TBL] [Abstract][Full Text] [Related]
15. Continuous administration of bevacizumab plus capecitabine, even after acquired resistance to bevacizumab, restored anti-angiogenic and antitumor effect in a human colorectal cancer xenograft model.
Iwai T; Sugimoto M; Harada S; Yorozu K; Kurasawa M; Yamamoto K
Oncol Rep; 2016 Aug; 36(2):626-32. PubMed ID: 27350037
[TBL] [Abstract][Full Text] [Related]
16. Antitumor activity of elacytarabine combined with bevacizumab, cetuximab and trastuzumab in human NSCLC xenografts.
Bruheim S; Sandvold ML; Mælandsmo GM; Fodstad O
Anticancer Res; 2013 Sep; 33(9):3615-21. PubMed ID: 24023287
[TBL] [Abstract][Full Text] [Related]
17. TLR9 agonist acts by different mechanisms synergizing with bevacizumab in sensitive and cetuximab-resistant colon cancer xenografts.
Damiano V; Caputo R; Garofalo S; Bianco R; Rosa R; Merola G; Gelardi T; Racioppi L; Fontanini G; De Placido S; Kandimalla ER; Agrawal S; Ciardiello F; Tortora G
Proc Natl Acad Sci U S A; 2007 Jul; 104(30):12468-73. PubMed ID: 17636117
[TBL] [Abstract][Full Text] [Related]
18. Effects of palifermin on antitumor activity of chemotherapeutic and biological agents in human head and neck and colorectal carcinoma xenograft models.
Brake R; Starnes C; Lu J; Chen D; Yang S; Radinsky R; Borges L
Mol Cancer Res; 2008 Aug; 6(8):1337-46. PubMed ID: 18708365
[TBL] [Abstract][Full Text] [Related]
19. Targeted Therapy for Resistant Cholangiocarcinoma with Bevacizumab or Cetuximab Added to Failed Cytotoxic Drug Cores.
Bruckner HW; Hirschfeld A; Schwartz M
Anticancer Res; 2016 Jan; 36(1):399-402. PubMed ID: 26722072
[TBL] [Abstract][Full Text] [Related]
20. Effects of convection-enhanced delivery of bevacizumab on survival of glioma-bearing animals.
Wang W; Sivakumar W; Torres S; Jhaveri N; Vaikari VP; Gong A; Howard A; Golden EB; Louie SG; Schönthal AH; Hofman FM; Chen TC
Neurosurg Focus; 2015 Mar; 38(3):E8. PubMed ID: 25727230
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
